A Practitioner's Toolkit for Managing the Menopause

References

• Position statement: Management of osteoporosis in postmenopausal women: 2010 position statement of The North American Menopause Society. Menopause 2010;17:25–54
   PubMed Web of Science ®Google Scholar
• de Villiers TJ, Pines A, Panay N, et al. Updated 2013 International Menopause Society recommendations on menopausal hormone therapy and preventive strategies for midlife health. Climacteric 2013;16:316–37
   PubMed Web of Science ®Google Scholar
• Santen RJ, Allred DC, Ardoin SP, et al. Postmenopausal hormone therapy: An Endocrine Society Scientific Statement. J Clin Endocrinol Metab 2010;95(7 Suppl 1):S1–66
   PubMedGoogle Scholar
• Wierman ME, Basson R, Davis SR, et al. Androgen therapy in women: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab 2006;91:3697–710
   PubMed Web of Science ®Google Scholar
• National Institutes of Health State-of-the-Science Conference Statement: management of menopause-related symptoms. Ann Intern Med 2005;142:1003–13
   PubMedGoogle Scholar
• Bell RJ, Lijovic M, Fradkin P, Davis SR. A pragmatic approach to the classification of menopausal status for community-based research. Menopause 2008;15:978–83
   PubMed Web of Science ®Google Scholar
• Gold EB, Crawford SL, Avis NE, et al. Factors related to age at natural menopause: longitudinal analyses from SWAN. Am J Epidemiol 2013;178:70–83
   PubMed Web of Science ®Google Scholar
• Qiu C, Chen H, Wen J, et al. Associations between age at menarche and menopause with cardiovascular disease, diabetes, and osteoporosis in Chinese women. J Clin Endocrinol Metab 2013;98:1612–21
   PubMed Web of Science ®Google Scholar
• Castelo-Branco C, Blumel JE, Chedraui P, et al. Age at menopause in Latin America. Menopause 2006;13:706–12
   PubMed Web of Science ®Google Scholar
• Harlow SD, Gass M, Hall JE, et al. Executive summary of the Stages of Reproductive Aging Workshop + 10: addressing the unfinished agenda of staging reproductive aging. J Clin Endocrinol Metab 2012;97:1159–68
   PubMed Web of Science ®Google Scholar
• Zumoff B, Strain GW, Miller LK, Rosner W. Twenty-four hour mean plasma testosterone concentration declines with age in normal premenopausal women. 1995;80:1429–30
   Google Scholar
• Davison SL, Bell R, Donath S, Montalto JG, Davis SR. Androgen levels in adult females: changes with age, menopause, and oophorectomy. J Clin Endocrinol Metab 2005;90:3847–53
   PubMed Web of Science ®Google Scholar
• Burger HG, Dudley EC, Cui J, Dennerstein L, Hopper JL. A prospective longitudinal study of serum testosterone, dehydroepiandrosterone sulfate, and sex hormone-binding globulin levels through the menopause transition. J Clin Endocrinol Metab 2000;85:2832–8
   PubMed Web of Science ®Google Scholar
• Judd HL, Lucas WE, Yen SS. Effect of oophorectomy on circulating testosterone and androstenedione levels in patients with endometrial cancer. Am J Obstet Gynecol 1974;118: 793–8
   PubMed Web of Science ®Google Scholar
• van der Stege JG, Groen H, van Zadelhoff SJ, et al. Decreased androgen concentrations and diminished general and sexual well-being in women with premature ovarian failure. Menopause 2008;15:23–31
   PubMed Web of Science ®Google Scholar
• Kalantaridou SN, Calis KA, Vanderhoof VH, et al. Testosterone deficiency in young women with 46,XX spontaneous premature ovarian failure. Fertil Steril 2006;86:1475–82
   PubMed Web of Science ®Google Scholar
• Van Look PF, Lothian H, Hunter WM, Michie EA, Baird DT. Hypothalamic-pituitary-ovarian function in perimenopausal women. Clin Endocrinol 1977;7:13–31
   PubMed Web of Science ®Google Scholar
• Gold EB, Colvin A, Avis N, et al. Longitudinal analysis of the association between vasomotor symptoms and race/ethnicity across the menopausal transition: Study of Women’s Health Across the Nation. Am J Public Health 2006;96:1226–35
   PubMed Web of Science ®Google Scholar
• Mishra GD, Kuh D. Health symptoms during midlife in relation to menopausal transition: British prospective cohort study. BMJ 2012;344:e402
   PubMed Web of Science ®Google Scholar
• Avis NE, Brockwell S, Randolph JF Jr, et al. Longitudinal changes in sexual functioning as women transition through menopause: results from the Study of Women’s Health Across the Nation. Menopause 2009;16:442–52
   PubMed Web of Science ®Google Scholar
• Chuni N, Sreeramareddy CT. Frequency of symptoms, determinants of severe symptoms, validity of and cut-off score for Menopause Rating Scale (MRS) as a screening tool: a cross-sectional survey among midlife Nepalese women. BMC Women’s Health 2011;11:30
   PubMed Web of Science ®Google Scholar
• Olaolorun FM, Lawoyin TO. Experience of menopausal symptoms by women in an urban community in Ibadan, Nigeria. Menopause 2009;16:822–30
   PubMed Web of Science ®Google Scholar
• Waidyasekera H, Wijewardena K, Lindmark G, Naessen T. Menopausal symptoms and quality of life during the menopausal transition in Sri Lankan women. Menopause 2009;16:164–70
   PubMed Web of Science ®Google Scholar
• Blumel JE, Chedraui P, Baron G, et al. A large multinational study of vasomotor symptom prevalence, duration, and impact on quality of life in middle-aged women. Menopause 2011;18: 778–85
   PubMed Web of Science ®Google Scholar
• Vikstrom J, Spetz Holm AC, Sydsjo G, Marcusson J, Wressle E, Hammar M. Hot flushes still occur in a population of 85-year-old Swedish women. Climacteric 2013;16:453–9
   PubMed Web of Science ®Google Scholar
• Kroenke CH, Caan BJ, Stefanick ML, et al. Effects of a dietary intervention and weight change on vasomotor symptoms in the Women’s Health Initiative. Menopause 2012;19:980–8
   PubMed Web of Science ®Google Scholar
• Elavsky S, Gonzales JU, Proctor DN, Williams N, Henderson VW. Effects of physical activity on vasomotor symptoms: examination using objective and subjective measures. Menopause 2012;19:1095–103
   PubMed Web of Science ®Google Scholar
• de Villiers TJ, Gass ML, Haines CJ, et al. Global Consensus Statement on menopausal hormone therapy. Climacteric 2013;16: 203–4
   PubMed Web of Science ®Google Scholar
• Estrogen and progestogen use in peri- and postmenopausal women: March 2007 position statement of The North American Menopause Society. Menopause 2007;14:168–82
   PubMed Web of Science ®Google Scholar
• Chrisman C, Ribeiro P, Dalton VK. The levonorgestrel- releasing intrauterine system: an updated review of the contraceptive and noncontraceptive uses. Clin Obstet Gynecol 2007;50:886–97
   PubMed Web of Science ®Google Scholar
• Simon JA. What if the Women’s Health Initiative had used transdermal estradiol and oral progesterone instead? Menopause 2014;21:769–83
   PubMed Web of Science ®Google Scholar
• Fournier A, Fabre A, Mesrine S, Boutron-Ruault MC, Berrino F, Clavel-Chapelon F. Use of different postmenopausal hormone therapies and risk of histology- and hormone receptor-defined invasive breast cancer. J Clin Oncol 2008;26:1260–8
   PubMed Web of Science ®Google Scholar
• Leonetti H, Longo S, Anasti J. Transdermal progesterone cream for vasomotor symptoms and postmenopausal bone loss. Obstet Gynecol 1999;94:225–8
   PubMed Web of Science ®Google Scholar
• Leonetti HB, Wilson KJ, Anasti JN. Topical progesterone cream has an antiproliferative effect on estrogen stimulated endometrium. Fertil Steril 2003;79:221–2
   PubMed Web of Science ®Google Scholar
• Cooper A, Spencer MI, Whitehead M, Ross D, Barnard GJR, Collins WP. Systemic absorption of progesterone from Progest cream in postmenopausal women. Lancet 1998;351:1255
   PubMed Web of Science ®Google Scholar
• Birkhauser MH, Panay N, Archer DF, et al. Updated practical recommendations for hormone replacement therapy in the peri- and postmenopause. Climacteric 2008;11:108–23
   PubMed Web of Science ®Google Scholar
• Nijland EA, Weijmar Schultz WC, Nathorst-Boos J, et al. Tibolone and transdermal E2/NETA for the treatment of female sexual dysfunction in naturally menopausal women: results of a randomized active-controlled trial. J Sex Med 2008;5:646–56
   PubMed Web of Science ®Google Scholar
• Cummings SR, Ettinger B, Delmas PD, et al. The effects of tibolone in older postmenopausal women. N Engl J Med 2008;359:697–708
   PubMed Web of Science ®Google Scholar
• Pinkerton JV, Abraham L, Bushmakin AG, et al. Evaluation of the efficacy and safety of bazedoxifene/conjugated estrogens for secondary outcomes including vasomotor symptoms in postmenopausal women by years since menopause in the Selective Estrogens, Menopause and Response to Therapy (SMART) Trials. J Womens Health (Larchmt) 2014;23:18–28
   PubMed Web of Science ®Google Scholar
• Mirkin S, Komm BS, Pan K, Chines AA. Effects of bazedoxifene/conjugated estrogens on endometrial safety and bone in postmenopausal women. Climacteric 2013;16:338–46
   PubMed Web of Science ®Google Scholar
• de Villiers TJ, Chines AA, Palacios S, et al. Safety and tolerability of bazedoxifene in postmenopausal women with osteoporosis: results of a 5-year, randomized, placebo-controlled phase 3 trial. Osteoporos Int 2011;22:567–76
   PubMed Web of Science ®Google Scholar
• Pinkerton JV, Komm BS, Mirkin S. Tissue selective estrogen complex combinations with bazedoxifene/conjugated estrogens as a model. Climacteric 2013;16:618–28
   PubMed Web of Science ®Google Scholar
• Portman DJ, Bachmann GA, Simon JA. Ospemifene, a novel selective estrogen receptor modulator for treating dyspareunia associated with postmenopausal vulvar and vaginal atrophy. Menopause 2013;20:623–30
   PubMed Web of Science ®Google Scholar
• Simon J, Portman D, Mabey RG Jr. Long-term safety of ospemifene (52-week extension) in the treatment of vulvar and vaginal atrophy in hysterectomized postmenopausal women. Maturitas 2014;77:274–81
   PubMed Web of Science ®Google Scholar
• Shams T, Firwana B, Habib F, et al. SSRIs for hot flashes: a systematic review and meta-analysis of randomized trials. J Gen Intern Med 2014;29:204–13
   PubMed Web of Science ®Google Scholar
• Salmi T, Punnonen R. Clonidine in the treatment of menopausal symptoms. Int J Gynaecol Obstet 1979;16:422–6
   PubMedGoogle Scholar
• Lindsay R, Hart DM. Failure of response of menopausal vasomotor symptoms to clonidine. Maturitas 1978;1:21–5
   PubMed Web of Science ®Google Scholar
• Bolli P, Simpson FO. Clonidine in menopausal flushing: a double-blind trial. N Z Med J 1975;82:196–7
   PubMed Web of Science ®Google Scholar
• Pandya KJ, Raubertas RF, Flynn PJ, et al. Oral clonidine in postmenopausal patients with breast cancer experiencing tamoxifen-induced hot flashes: a University of Rochester Cancer Center Community Clinical Oncology Program study. Ann Intern Med 2000;132:788–93
   PubMed Web of Science ®Google Scholar
• Lavigne JE, Heckler C, Mathews JL, et al. A randomized, controlled, double-blinded clinical trial of gabapentin 300 versus 900 mg versus placebo for anxiety symptoms in breast cancer survivors. Breast Cancer Res Treat 2012;136:479–86
   PubMed Web of Science ®Google Scholar
• Pandya KJ, Morrow GR, Roscoe JA, et al. Gabapentin for hot flashes in 420 women with breast cancer: a randomised double-blind placebo-controlled trial. Lancet 2005;366:818–24
   PubMed Web of Science ®Google Scholar
• Nguyen ML. The use of pregabalin in the treatment of hot flashes. Can Pharm J 2013;146:193–6
   Google Scholar
• Elkins GR, Fisher WI, Johnson AK, Carpenter JS, Keith TZ. Clinical hypnosis in the treatment of postmenopausal hot flashes: a randomized controlled trial. Menopause 2013;20:291–8
   PubMed Web of Science ®Google Scholar
• Mann E, Smith MJ, Hellier J, et al. Cognitive behavioural treatment for women who have menopausal symptoms after breast cancer treatment (MENOS 1): a randomised controlled trial. Lancet Oncol 2012;13:309–18
   PubMed Web of Science ®Google Scholar
• Ayers B, Hunter MS. Health-related quality of life of women with menopausal hot flushes and night sweats. Climacteric 2013;16:235–9
   PubMed Web of Science ®Google Scholar
• Lipov EG, Joshi JR, Sanders S, et al. Effects of stellate-ganglion block on hot flushes and night awakenings in survivors of breast cancer: a pilot study. Lancet Oncol 2008;9:523–32
   PubMed Web of Science ®Google Scholar
• Davis SR, Davison SL, Donath S, Bell R. Relationships between circulating androgen levels and self-reported sexual function in women. JAMA 2005;294:91–6
   PubMed Web of Science ®Google Scholar
• Simon J, Braunstein G, Nachtigall L, et al. Testosterone patch increases sexual activity and desire in surgically menopausal women with hypoactive sexual desire disorder. J Clin Endocrinol Metab 2005;90:5226–33
   PubMed Web of Science ®Google Scholar
• Davis SR, Moreau M, Kroll R, et al. Testosterone for low libido in menopausal women not taking estrogen therapy. N Engl J Med 2008;359:2005–17
   PubMed Web of Science ®Google Scholar
• Panay N, Al-Azzawi F, Bouchard C, et al. Testosterone treatment of HSDD in naturally menopausal women: the ADORE study. Climacteric 2010;13:121–31
   PubMed Web of Science ®Google Scholar
• Davis SR, Panjari M, Stanczyk FZ. DHEA replacement for postmenopausal women. J Clin Endocrinol Metab 2011;96:1642–53
   PubMed Web of Science ®Google Scholar
• Alkatib AA, Cosma M, Elamin MB, et al. A systematic review and meta-analysis of randomized placebo-controlled trials of DHEA treatment effects on quality of life in women with adrenal insufficiency. J Clin Endocrinol Metab 2009;94:3676–81
   PubMed Web of Science ®Google Scholar